The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
=== No development reported === ACH-36 – undefined mechanism of action [22] Alprazolam sublingual – GABAA receptor positive allosteric modulator and benzodiazepine [23] Antalarmin (CP-154526) – corticotropin-releasing hormone (CRH) inhibitor [24] Buspirone controlled release (Buspirone ER) – serotonin 5-HT1A receptor partial agonist and other actions [25] BW-723C86 – serotonin 5-HT2B and 5-HT2C receptor agonist [26] Cannabidiol dry powder inhalation (RLS-103) – cannabinoid receptor modulator and other actions [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Divaplon (RU-32698) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazolpyrimidine [29] Fananserin (RP-62203) – serotonin 5-HT2A receptor antagonist and dopamine D4 receptor antagonist [30] FR260010 (FR-260010) – serotonin 5-HT2C receptor antagonist [31] [32] GSK-588045 (GSK588045) – serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptor antagonist [33] GSK-1360707 – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) [34] GT-001 – GABAA receptor positive allosteric modulator [35] Guanfacine extended release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist [36] Itriglumide (CR-2945) – cholecystokinin B (CCKB) receptor antagonist [37] Lohocla-201 (Kindolor) – various actions [38] LY-293284 – serotonin 5-HT1A receptor agonist [39] NMRA-511 (BTRX-323511; NMRA-323511) – vasopressin V1A receptor antagonist [40] Paroxetine (Aropax; BRL-29060; Deroxat; Divarius; FG-7051; Frosinor; Motivan; NNC-207051; Paxil; Seroxat; SI-211103; Tagonis) – selective serotonin reuptake inhibitor (SSRI) [41] Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen [42] PT-00114 (PT100114) – corticotropin-releasing hormone (CRH) inhibitor [43] Research programme: allosteric modulators - Addex Therapeutics – various actions [44] Research programme: AMPA receptor agonists - RespireRx (ampakines; CX compounds) – AMPA receptor agonists and brain-derived neurotrophic factor (BDNF) stimulants [45] Research programme: anxiety and neurological disorder therapeutics - AstraZeneca – various actions [46] Research programme: cannabis-based therapeutics - Skye Bioscience – cannabinoid receptor agonists [47] Research programme: neuropeptide S receptor modulators - Pfizer (WYE-198232) – neuropeptide receptor agonists [48] Research programme: oxytocin receptor agonist - Wyeth – oxytocin receptor agonists [49] RGH-618 – metabotropic glutamate mGlu5 receptor negative allosteric modulator [50] Riluzole (PK-26124; Rilutek; RP-54274) – various actions [51] Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) [52] Saripidem (SL-850274) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [53] SB-242084 (SB242084) – serotonin 5-HT2C receptor antagonist [54] SRX-246 (API-246) – vasopressin V1A receptor antagonist [55] SYT-510 – anandamide reuptake inhibitor [56] Tebideutorexant (JNJ-3215; JNJ-61393215; Orexin-1) – orexin OX1 receptor antagonist [57] WAY-100135 – serotonin 5-HT1A receptor antagonist [58] Ziprasidone (CP-88059-01; CP-88059-1; Geodon; ME-2112; RQ-00000003; Zeldox) – atypical antipsychotic (non-selective monoamine receptor modulator) [59]
Synthesis starts with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give the N-nitroso derivative. Reduction by means of sodium thiosulfate leads to the transient hydrazine (3), which undergoes spontaneous internal hydrazide formation. Treatment of the enolate of this amide with 3-chloro-1-dimethylamino propane gives benzydamine (5). Please note there is an error in this section: US3318905 states that the nitroso derivative is reduced with sodium hydrosulfite (sodium dithionite) and not with sodium hyposulfite (sodium thiosulfate), as shown in the above scheme and stated in text.
Osborne's ligament, also Osborne's band, Osborne's fascia, Osborne's arcade, arcuate ligament of Osborne, or the cubital tunnel retinaculum, refers to either the connective tissue which spans the humeral and ulnar heads of the flexor carpi ulnaris (FCU) or another distinct tissue located between the olecranon process of the ulna and the medial epicondyle of the humerus. It is named after Geoffrey Vaughan Osborne, a British orthopedic surgeon, who described the eponymous tissue in 1957.
=== Liver Disease === Bhatia's doctoral work laid the foundation for keeping liver cells functional outside the human body. By adapting techniques from computer chip design and photolithography, she microfabricated substrates that support the growth and function of 2D and 3D human liver cells in a lab dish. This led to the invention of the "microliver," a miniature model organ that revolutionized the efficient testing of drug reactions. It is now used globally by companies to evaluate drug efficacy and predict toxic side effects. Further research in her lab, including the use of 3D printing to create synthetic vascular systems, aims to develop larger tissue structures with the ultimate goal of an artificial human liver. This foundational work was among the first at MIT in the area of biological micro-electromechanical systems (Bio-MEMS). The LMRT continues to apply micro- and nanotechnology to tissue repair and regeneration, studying the interactions between hepatocytes (liver cells) and their microenvironment. This work improves cellular therapies for liver disease, maximizes hepatocyte function, and enhances the understanding of liver physiology and pathophysiology. Her research has been instrumental in studying diseases like hepatitis and malaria. In collaboration with Christopher Chen at Boston University, Bhatia's lab developed human microlivers that can be transplanted, vascularized, and survive in vivo, offering potential curative therapies for both heritable and acquired liver diseases.
=== Social pressures === Social pressure is one of the factors that leads to doping in sport. The media and society work together to construct a view of what masculinity and femininity should look like. Adolescent athletes are constantly influenced by what they see on the media, and some go to extreme measures to achieve the ideal image since society channels Judith Butler's definition of gender as a performative act. Examples of social pressures were given in a study done on an online bodybuilding community where bodybuilders doped because they felt like it was a rite of passage to be accepted into the community, and to feel validated. Both men and women are being materialized in the context of doping in sport; in an interview involving 140 men, it was concluded that "bodily practices are essential for masculine identity," and it was determined that the media highly publicizes female athletes who were strong, and thin. This leads to the issue of the consumption of performance enhancement drugs to achieve muscular or thin figures, and the assumption that the opponents are also taking performance-enhancing drugs, deeming it as an acceptable behavior to conform to. In addition, society's embracement of the "winning is everything" spirit leads many athletes to participate in doping, hoping that they will not be caught.
Sources: en.wikipedia.org
=== Autism spectrum disorder === Unlike ADHD, which significantly increases the risk of substance use disorder, autism spectrum disorder has the opposite effect of significantly reducing the risk of substance use. This is because introversion, inhibition and lack of sensation seeking personality traits, which are typical of autism spectrum disorder, protect against substance use and thus substance use levels are low in individuals who are on the autism spectrum. However, certain forms of substance use disorders, especially alcohol use disorder, can cause or worsen certain neuropsychological symptoms which are common to autism spectrum disorder. This includes impaired social skills due to the neurotoxic effects of alcohol on the brain, especially in the prefrontal cortex area of the brain. The social skills that are impaired by alcohol use disorder include impairments in perceiving facial emotions, prosody perception problems and theory of mind deficits; the ability to understand humour is also impaired in people who consume excessive amounts of alcohol.
R-CH=CH-CO-SCoA + H2O2 Hydrogen peroxide arises by the degradation of adenosine monophosphate, which yields hypoxanthine. Hypoxanthine is then oxidatively catabolized first to xanthine and then to uric acid, and the reaction is catalyzed by the enzyme xanthine oxidase:
Gerald (Jerry) Ledlow, Dean of UT Health Science Center at Tyler School of Community and Rural Health; Erich Heneke, Director of Business Integrity Continuity in Mayo Clinic's Supply Chain Management (SCM); Mike Loughrin, President of Transformance Advisors; Renata Rieder, Head of Service Management at Federal Office of Information Technology, Systems and Telecommunication for the Government of Switzerland; David Jacoby, President of Boston Strategies International; and Jorge A. Morales, former RFID technology advisor to the Mexican Government.
Dr. Reddy's originally launched in 1984 producing active pharmaceutical ingredients. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognised brand in India. Soon, Dr. Reddy's obtained another success with Omez, its branded omeprazole – gastrointestinal ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time. Within a year, Reddy's became the first Indian company to export the active ingredients for pharmaceuticals to Europe. In 1987, Reddy's started to transform itself from a supplier of pharmaceutical ingredients to other manufacturers into a manufacturer of pharmaceutical products. In 1999, Dr. Reddy's joined the Indian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.